Unterehmen auf Watchlist setzen
ADMA Biologics
ISIN: US0008991046
WKN: A12FAG
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

ADMA Biologics · ISIN: US0008991046 · Business Wire (ID: 20241105309657)
05 November 2024 03:59PM

ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm


ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA) for violations of the securities laws.

According to the Complaint, the Company made false and misleading statements to the market. ADMA Biologics admitted the abrupt resignation of its independent outside auditor, CohnReznick LLP., on October 9, 2024. The Company’s shares lost more than 16.3% the next day based on this news.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contact

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

Visuelle Wertentwicklung / Kursverlauf · ADMA Biologics
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner Business Wire
BusinessWire
via BusinessWire - Newsfeed
BusinessWire ©2024
BusinessWire
Kontakt:
101 California Street, 20th Floor San Francisco, CA, 94111 United States
+1.415.986.4422